INTRODUCTION: Hepatitis C virus (HCV)-specific T lymphocyte responses have been demonstrated in peripheral blood from injection drug users (IDUs) persistently HCV antibody and RNA negative despite high-risk behavior. We have termed these apparently HCV resistant cases "Exposed Uninfecteds" (EUs), and have studied the evolution of T-cell responses to determine if they are protective in nature. METHODS: Twenty-one EU cases were studied using a questionnaire to ascertain injecting behavior details. Peripheral blood mononuclear cells were isolated from whole blood and an interferon-gamma (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay used to detect T-cell responses to a panel of HCV proteins. EU cases were subdivided by injecting drug patterns into (1) cases in rehabilitation who stopped injecting, (2) prisoners (infrequent/noninjectors), and (3) cases who continued to inject. RESULTS: EUs continuing to inject had significantly stronger (P < .01) and more frequent (P < .05) HCV-specific IFN-γ ELISPOT responses than controls or noninjecting EUs. EUs in rehabilitation lost their T-cell responses during follow-up, while those continuing to inject maintained them. CONCLUSIONS: HCV-specific T-cell responses in EU cases wane within months of cessation of injection drug use. Maintenance of these T-cell responses appears to be dependent on continuing HCV exposure through injection drug use.
INTRODUCTION:Hepatitis C virus (HCV)-specific T lymphocyte responses have been demonstrated in peripheral blood from injection drug users (IDUs) persistently HCV antibody and RNA negative despite high-risk behavior. We have termed these apparently HCV resistant cases "Exposed Uninfecteds" (EUs), and have studied the evolution of T-cell responses to determine if they are protective in nature. METHODS: Twenty-one EU cases were studied using a questionnaire to ascertain injecting behavior details. Peripheral blood mononuclear cells were isolated from whole blood and an interferon-gamma (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay used to detect T-cell responses to a panel of HCV proteins. EU cases were subdivided by injecting drug patterns into (1) cases in rehabilitation who stopped injecting, (2) prisoners (infrequent/noninjectors), and (3) cases who continued to inject. RESULTS: EUs continuing to inject had significantly stronger (P < .01) and more frequent (P < .05) HCV-specific IFN-γ ELISPOT responses than controls or noninjecting EUs. EUs in rehabilitation lost their T-cell responses during follow-up, while those continuing to inject maintained them. CONCLUSIONS:HCV-specific T-cell responses in EU cases wane within months of cessation of injection drug use. Maintenance of these T-cell responses appears to be dependent on continuing HCV exposure through injection drug use.
Authors: R Kaul; T Dong; F A Plummer; J Kimani; T Rostron; P Kiama; E Njagi; E Irungu; B Farah; J Oyugi; R Chakraborty; K S MacDonald; J J Bwayo; A McMichael; S L Rowland-Jones Journal: J Clin Invest Date: 2001-05 Impact factor: 14.808
Authors: Anthony J Freeman; Rosemary A Ffrench; Jeffrey J Post; Charles E Harvey; Stuart J Gilmour; Peter A White; George Marinos; Ingrid van Beek; William D Rawlinson; Andrew R Lloyd Journal: J Infect Dis Date: 2004-08-10 Impact factor: 5.226
Authors: D Hegazy; P Thurairajah; M Metzner; A Houldsworth; S Shaw; E Kaminski; A G Demaine; M E Cramp Journal: Clin Exp Immunol Date: 2008-04-16 Impact factor: 4.330
Authors: Eishiro Mizukoshi; Christoph Eisenbach; Brian R Edlin; Kimberly P Newton; Sukanya Raghuraman; Christina Weiler-Normann; Leslie H Tobler; Michael P Busch; Mary Carrington; Jane A McKeating; Thomas R O'Brien; Barbara Rehermann Journal: J Infect Dis Date: 2008-07-15 Impact factor: 5.226
Authors: Jeffrey J Post; Yong Pan; Anthony J Freeman; Charles E Harvey; Peter A White; Patricia Palladinetti; Paul S Haber; George Marinos; Michael H Levy; John M Kaldor; Kate A Dolan; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson Journal: J Infect Dis Date: 2004-04-26 Impact factor: 5.226
Authors: M Zeremski; M A Shu; Q Brown; Y Wu; D C Des Jarlais; M P Busch; A H Talal; B R Edlin Journal: J Viral Hepat Date: 2008-07-17 Impact factor: 3.728